Related Experiment Video
Updated: Mar 10, 2026

Murine Corneal Transplantation: A Model to Study the Most Common Form of Solid Organ Transplantation
Published on: November 17, 2014
Corneal graft rejection in a patient treated with nivolumab for primary lung cancer
S Le Fournis1, P Gohier2, T Urban3
1LUNAM Université, 49 000 Angers, France; Université d'Angers, CHU Angers, Pôle des Spécialités Médicales et Chirurgicales Intégrées, Service de Pneumologie, 49 000 Angers, France.
Abstract:
We report the case of a 58-year-old woman treated with nivolumab for an unresectable squamous non-small cell lung cancer, after first-line cisplatin and gemcitabine combination chemotherapy. This woman had a history of left corneal graft. After 9 cycles of nivolumab, the patient described decreased visual acuity in the left eye with watering and conjunctival erythema. Ophthalmological examination revealed chronic corneal graft rejection. The patient was then treated with an intravenous bolus of corticosteroids (500mg of methylprednisolone) for 3 days, followed by oral prednisone for 4 weeks and subconjunctival corticosteroid injections every 48h, while treatment with nivolumab was discontinued. No clinical benefit was observed 4 weeks later and the corneal graft became totally unfunctional despite of the therapy. We hypothesise that the treatment was started too late. To our knowledge, this is the first reported case of corneal graft rejection related to nivolumab.
Related Concept Videos
Treatment Resistant Cancers
Tumor Immunotherapy

